How Does DT1 Sphere Perform in Current and Successful Acuvue MAX Wearers?

NCT ID: NCT06847230

Last Updated: 2025-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-15

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this prospective study is to to understand if satisfied MAX Contact lens (CL)wearers can be successfully refit into Dailies total 1 (DT1) CL in healthy MAX CL wearers between the ages of 18-40. The main question is to determine the number of participants who can successfully be re-fit into DT1 CL, by utilizing a cldeq-8 questionnaire as well as an investigator developed questionnaire to gauge comfort and satisfaction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contact Lens Comfort and Successful Refitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This 2-week, 3-visit clinical study will refit current Acuvue Max contact lens wearers into Dailies Total 1 contact lenses
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dailies total 1 contact lenses

Acuvue max wearers will be refit into dailies total 1

Group Type EXPERIMENTAL

Dailies total 1 contact lenses

Intervention Type DEVICE

successful refit into dt1 will be determined

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dailies total 1 contact lenses

successful refit into dt1 will be determined

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults, 18- to 40-year-old, Oasys MAX 1-day CL wearers with best-corrected 20/20 visual acuity or better.
* Participants will be required to have worn Oasys MAX 1-day CLs for at least 3 months in the past year and currently wearing these CLs.
* All participants will be required to have a CLDEQ-8 score \<12 while wearing their habitual CLs (Oasys MAX 1-days) and to indicate that they are satisfied with Oasys MAX 1-day CLs (Yes/No).
* Participants will be required to be able to wear DT1 Sphere CLs (astigmatism \< 0.75D OD/OS).
* Participants will be required to wear the study CLs for ≥12 hours with no overnight wear
* Participants will be required to use digital devices at least 8 hours/day.
* Participants will be required to provide a glasses prescription that is less than 3 years old.

Exclusion Criteria

* Have presbyopia and/or need a reading add as determined during their initial manifest refraction.
* Have worn DT1 in the past for more than 1 week.
* Are past rigid CL wearers.
* Have a history of being diagnosed with dry eye or ocular allergies.
* Have known systemic health conditions that are thought to alter tear film physiology.
* Have corrected acuity 1 line or more worse vision recorded at Visit 2 (compared to the Visit 1 findings) with their optimized Oasys MAX 1-day lenses.
* Have a history of viral eye disease.
* Have a history of ocular surgery.
* Have a history of severe ocular trauma.
* Have a history of corneal dystrophies or degenerations.
* Have active ocular infection or inflammation.
* Are currently using isotretinoin-derivatives or ocular medications.
* Are pregnant or breast feeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Southern College of Optometry

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Southern College of Optometry

Memphis, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-07-01CL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.